CONTACTS
SUBJECTS
Default Null Subject Account for Blank Record
0403 -
0403 - ..
0404 - Summary/Objective
0405 -
040501 - Follow up ref SDS 14 0000, ref SDS 13 0000.
040502 -
040503 -
040504 -
040505 -
040507 - ..
0406 -
0407 -
0408 - Progress
0409 -
040901 - Visited Lab on ground floor VA in Martinez.
040902 -
040903 - On 111013, interim lab, ref SDS 14 GM65, for 6 - 8 weeks to test
040904 - results switching from Simvastatin to Rosuvastatin for managing
040905 - cholesterol, planned by Doctor Egan on 110817 1030, ref SDS 12 JQ5F,
040906 - and reported by Buena in a call earlier on 111013 1048. ref SDS 13 H291
040908 - ..
040909 - Lab today tests effectiveness reducing cholesterol LDL < 70 ordered by
040910 - Doctor Egan in a meeting at the VA in Martinez on 110817 1030,
040911 - ref SDS 12 JQ54, and reported by Ally on 111013 1404. ref SDS 14 EO7O
040913 - ..
040914 - Attendant said lab will test for...
040915 -
040916 - Lipid
040917 - Electrolyte
040918 - Myopathy
040920 - ..
040921 - Attendant said to expect results posted tomorrow.
040923 - ..
040924 - Total Bilirubin 1.3 Recovery Impaired Liver after Simvastatin
040925 - Salt Sodium Declines Near Danger Too Low
040926 - Glucose Declines Again Risk Diabetes Further Reduced
040927 -
040928 - Follow up ref SDS 14 GM65, ref SDS 11 GM65.
040930 - ..
040931 - CHEM PROFILE........... 2011 11 17 1427
040932 - PLASMA Results Units Range
040933 - GLUCOSE 108 mg/dL 74 - 118
040934 - GLUfast mg/dL Ref: <=99
040935 - NA (salt) 139 mmol/L 136 - 144
040936 - K 4.1 mmol/L 3.4 - 4.8
040937 - CL 103 mmol/L 98 - 106
040938 - CO2 30 mmol/L 23 - 33
040939 - BUN 11 mg/dL 8 - 26
040940 - CREAT 0.89 mg/dL .5 - 1.1
040941 - eGFR >60 mL/min Ref: >=60
040942 - CALCIUM 9.0 mg/dL 8.7 - 10.2
040943 - CA CORR mg/dL 8.7 - 10.2
040944 - PO4 mg/dL 2.4 - 4.5
040945 - MG mg/dL 1.8 - 2.5
040946 - ALK PHO 95 IntUnits/L 37 - 107
040947 - T. BIL 1.3 H mg/dL .3 - 1.2
040948 - D. BILI mg/dL .1 - .4
040949 - AST 25 IntUnits/L 8 - 42
040950 - ALT 24 IntUnits/L 5 - 55
040951 - ALBUMIN 4.4 g/dL 3.3 - 4.8
040952 - PROTEIN 7.4 g/dL 6.5 - 8.1
040953 - LDH IntUnits/L 90 - 208
040954 - AMYLASE Units/L 28 - 100
040955 - LIPASE Units/L 7 - 58
040956 - NH3 mcmol/L 15 - 56
040957 - URIC AC mg/dL 4.8 - 8.7
040958 - Comments: a
040960 - ..
040961 - a. TEST PERFORMED BY VA MARTINEZ, 150 MUIR ROAD, MARTINEZ CA.
040963 - ..
040964 - b. Evaluation for CREAT:
040965 -
040966 - Effective 7/2/08, new standardized method for
040967 - creatinine in place. Note reference range change.
040968 - Previous range 0.5-1.2 mg/dL.
040970 - ..
040971 - c. Evaluation for ALK PHO:
040972 -
040973 - The normal range is for an adult population less than
040974 - 50 years old. Alk Phos increases with age over 50 to
040975 - about 60% higher values by ages greater than 75 years
040976 - old.
040978 - ..
040979 - d. Evaluation for eGFR:
040980 -
040981 - eGFR Units = mL/min/1.73 square meters
040983 - ..
040984 - Glucose and salt (NA) both increase - reflect decline hiking from 40
040985 - to only 2 miles per week, past month or so, shown in case study on
040986 - 101010 0744. ref SDS 9 UT6K
040988 - ..
040989 - Total bilirubin 1.3 holding below 2.0 high in prior lab on 110727
040990 - 1238. ref SDS 11 GM65 - significant decline after ending Simvastatin,
040991 - shown by interim lab a few weeks ago on 111013 1404. ref SDS 14 557J
040992 - Hopefully indicates recovery of any impaired liver function, cited in
040993 - research on 111013 1404. ref SDS 14 LC8J
040994 -
040995 -
040996 -
040997 -
0410 -
SUBJECTS
Default Null Subject Account for Blank Record
0503 -
050401 - ..
050402 - LDL 200 Huge Increase Risk CAD Goal Reduce LDL < 70 Failed
050403 -
050404 - Follow up ref SDS 11 E19L, ref SDS 10 E19L.
050405 -
050406 - Work plan changed simvastatin 40 mg to rosuvastatin 10 mg on 110817
050407 - 1030. ref SDS 12 DG36 Lab today evaluate requirement increase dose
050408 - rosuvastatin 20 mg. 110817 1030, ref SDS 12 JQ54
050410 - ..
050411 - Assessment lab results shown below. ref SDS 0 RA5O
050412 -
050413 - LIPID PANEL............ 2011 11 17 1427
050414 - PLASMA Results Units Range
050415 - CHOL 260 H mg/dL Ref: <=200
050416 - TRIGLYC 84 mg/dL Ref: <=150
050417 - HDL 43 mg/dL Ref: >=40
050418 - LDL 200 H mg/dL Ref: <=160
050419 - LDL Dir mg/dL Ref: <=160
050420 - TRIG NF mg/dL Ref: <=150
050421 - Comments: a
050422 -
050441 - ..
050442 - Research indicates LDL is presented 2 ways: calculated, which is less
050443 - accurate, and direct, which is more expensive.
050445 - ..
050446 - Research also indicates tests for LDL cholesterol are not reliable,
050447 - shown below, ref SDS 0 N29Y, so hard to decide course of action.
050448 -
050450 - ..
050451 - Lipid History....
050453 - ..
050454 - See assessment of lab results, below. ref SDS 0 RA5O
050455 -
050456 - Collection DT Spec CHOLESTEROL Target Range
050457 - 111117 0215 PLASM 260 H mg/dL <= 200 ...... ref SDS 0 IM9N
050458 - 110727 1238 PLASM 163 ........................... ref SDS 11 E19L
050459 - 101207 0906 PLASM 151 ........................... ref SDS 10 E19L
050460 - 100721 0800 PLASM 261 H ........................... ref SDS 8 E19L
050461 - 100610 1033 PLASM 217 H ........................... ref SDS 7 QV4F
050462 - 090813 1500 PLASM 233 H ........................... ref SDS 5 8P5F
050463 - 060616 1059 PLASM 238 H ........................... 060623 0840, ref SDS 4 UO6K
050464 - 050906 1204 PLASM 257 H ........................... ref SDS 2 DG8G
050465 - 050709 1000 PLASM 277 H ........................... ref SDS 1 G69K
050467 - ..
050468 - Graph of cholesterol shown on 090813 1500. ref SDS 5 NQ86
050470 - ..
050471 - Graph of HDL and LDL are primary risk factors for CAD, see graph
050472 - below. ref SDS 0 7M42
050474 - ..
050475 - TRIGLYC
050476 - 111117 0215 PLASM 84 mg/dL <= 150 ...... ref SDS 0 IM9N
050477 - 110727 1238 PLASM 81 ........................... ref SDS 11 E19L
050478 - 101207 0906 PLASM 41 ........................... ref SDS 10 E19L
050479 - 100721 0800 PLASM 87 ........................... ref SDS 8 E19L
050480 - 100610 1033 PLASM 83 ........................... ref SDS 7 QV4F
050481 - 090813 1500 PLASM 118 ........................... ref SDS 5 8P5F
050482 - 060616 1059 PLASM 68 ........................... 060623 0840, ref SDS 4 UO6K
050484 - ..
050485 - HDL
050486 - 111117 0215 PLASM 43 mg/dL >= 40 ...... ref SDS 0 IM9N
050487 - 110727 1238 PLASM 45 ........................... ref SDS 11 E19L
050488 - 101207 0906 PLASM 47 ........................... ref SDS 10 E19L
050489 - 100721 0800 PLASM 35 L ........................... ref SDS 8 E19L
050490 - 100610 1033 PLASM 36 L ........................... ref SDS 7 QV4F
050491 - 090813 1500 PLASM 30 L ........................... ref SDS 5 8P5F
050492 - 060616 1059 PLASM 32 L ........................... 060623 0840, ref SDS 4 UO6K
050494 - ..
050495 - LDL-CHO
050496 - 111117 0215 PLASM 200 H mg/dL <= 160 ...... ref SDS 0 IM9N
050497 - 110727 1238 PLASM 102 ........................... ref SDS 11 E19L
050498 - 101207 0906 PLASM 96 ........................... ref SDS 10 E19L
050499 - 100721 0800 PLASM 209 H ........................... ref SDS 8 E19L
050500 - 100610 1033 PLASM 164 H ........................... ref SDS 7 QV4F
050501 - 090813 1500 PLASM 179 H ........................... ref SDS 5 8P5F
050502 - 060616 1059 PLASM 192 H ........................... 060623 0840, ref SDS 4 UO6K
050503 -
050504 - [On 111128 0202 letter to medical team asks about
050505 - increasing medication to rosuvastatin 20 mg or trying some
050506 - other line of care in order to reduce cholesterol LDL < 70,
050507 - ref SDS 17 EB3U, according to the VA work plan on 110817
050508 - 1030. ref SDS 12 DG36
050510 - ..
050511 - [On 111128 2038 increased medication to rosuvastatin 20 mg,
050512 - shown in case study on patient history on 101010 0744.
050513 - ref SDS 9 NV7I
050515 - ..
050516 - Previously, 2 years ago, Doctor Egan assesd coronary artery disease
050517 - (CAD) correlates with research on hyperlipidemia in the record for
050518 - 091002 0900. ref SDS 6 8X3G Aligned with prior analysis by Doctor
050519 - Sandhu on 060505 0830. ref SDS 3 OE3L
050521 - ..
050522 - Hyperlipidemia - cholesterol risk factors reviewed also on 091002.
050523 - ref SDS 6 2F8K
050525 - ..
050526 - Currently, LDL 200 rising from 102 for prior lab on 110727 1238,
050527 - ref SDS 11 E19L, does not meet objective of LDL < 70, planned in
050528 - meeting at the VA prescribing rosuvastatin 10 mg to replace
050529 - simvastatin 40 mg, reported on 110817 1030. ref SDS 12 DG36
050531 - ..
050532 - HDL has not increased, also, conflicting with objectives at that time
050533 - on 110817 1030. ref SDS 12 IO6F
050535 - ..
050536 - Significant cholesterol rise to LDL 200 may reflect artery strictures
050537 - limiting blood flow possibly aligning with recent increase in blood
050538 - pressure, roughly averaging 115 75 from October 2010, until about a
050539 - month ago, shown in case study on 101010 0744. ref SDS 3 QJ5I
050540 - Beginning OA 111030, blood pressure suddenly increased to about 135
050541 - 75, with many readings above 145. ref SDS 3 UT6K At about that same
050542 - time hiking decreased from 40 down to 2 miles per week. In recent
050543 - days, blook pressure trending down slightly with hiking increased
050544 - back to 40 miles per week.
050546 - ..
050547 - Additionally, missed a week taking rosuvastatin 10 mg because forgot
050548 - to bring pills home from assignment providing case management in
050549 - Southern California, reported on 111105, also in case study.
050550 - ref SDS 3 WWSQ
050551 -
050552 -
050554 - ..
050555 - LDL Cholesterol 100 Point Changes Less than 3 Months
050556 - Large Variations LDL Less 3 Months Indicates Unreliable Testing
050557 -
050558 - Big increases in LDL over past 3 months correlates with similar
050559 - increase over 1 month last year on 100721 0800, ref SDS 8 PTPP, and
050560 - seems incongruous, undermining reliability of lipid testing.
050562 - ..
050563 - 210 mg/dL +209 (10721 0000 (ref SDS 8 E19L)
050564 - | |
050565 - 200 | +--+ +-- 200 (111117 0215, ref SDS 0 IM9N)
050566 - 192 (060623 0840, ref SDS 4 UO6K) | |
050567 - 190 | | | |
050568 - | | | |
050569 - 180 +-----/ /----- 179 (090813 1500, ref SDS 5 8P5F)
050570 - | | | |
050571 - 170 | | | |
050572 - | | | |
050573 - 160 +---------- 164 (100610 1046, ref SDS 7 QV4F)
050574 - | |
050575 - 150 | |
050576 - | |
050577 - 140 / |
050578 - | |
050579 - 130 | |
050580 - | |
050581 - 120 | |
050582 - | |
050583 - 110 | |
050584 - | +---- 102 (110727 0000, ref1SDS 11 E19L)
050585 - 100 | |
050586 - 96 (101207 0000, ref SDS 10 E19L)
050587 - 90
050588 -
050589 - 80
050590 - ..
050591 - 70 ==================== G O A L ==========================
050592 -
050593 - 60 Simvastatin Rosuvastatin
050594 - 091104 110817 111128. ref SDS 9 NV7I
050595 - 40 20 mg 40 mg 10 mg 20 mg
050596 -
050597 - 20
050598 - ..
050599 - 10
050600 - <---2006--->/../<---2009---><---2010---><---2011---><---2012--->
050601 - 1 3 6 9 1 3 6 9 1 3 6 9 1 3 6 9 1 3 6 9
050602 -
050603 -
050604 -
0507 -
SUBJECTS
Default Null Subject Account for Blank Record
0603 -
060401 - ..
060402 - Errors Common LDL Cholesterol Testing
060403 - LDL Testing Fraught with Error Test Results Variability
060404 -
060405 - Big changes of 100 mg/DL up and down in LDL cholesterol within 1 - 3
060406 - month intervals shown in patient history, per above. ref SDS 0 5X6U
060407 -
060408 - How can body chemestry change so quickly with diet and exercise
060409 - relatively stable?
060411 - ..
060412 - Research indicates reliability of lipid cholesterol testing has been a
060413 - problem since 1988, ref SDS 0 PUPU, and continues to the present day,
060414 - as shown in following article published by the National Health
060415 - Institute this year, saying testing for LDL cholesterol is "fraught
060416 - with error." ref SDS 0 N29Y
060418 - ..
060419 - Research on the Internet shows....
060420 -
060421 - 1. Pubmed.gov
060422 - US National Library of Medicine
060423 - National Institutes of Health
060425 - ..
060426 - Journal of Clinical Lipidology
060427 -
060428 - 2011 Jul-Aug 5(4) 264-72
060429 - Epub.................................... 2011 May 27
060431 - ..
060432 - Reliability of low-density lipoprotein cholesterol,
060433 - non-high-density lipoprotein cholesterol, and apolipoprotein B
060434 - measurement.
060435 -
060436 - http://www.ncbi.nlm.nih.gov/pubmed/21784371
060438 - ..
060439 - Maine Standards Company, 765 Roosevelt Trail, Windham, ME
060440 - 04062, USA. jcontois@mainestandards.com
060442 - ..
060443 - 1. Abstract
060444 -
060445 - There is little understanding of the reliability of laboratory
060446 - measurements among clinicians. Low-density lipoprotein
060447 - cholesterol (LDL-C) measurement is the cornerstone of
060448 - cardiovascular risk assessment and prevention, but it is
060449 - fraught with error.
060451 - ..
060452 - 2. Therefore, we have reviewed issues related to accuracy and
060453 - precision for the measurement of LDL-C and the related
060454 - markers non-high-density lipoprotein cholesterol
060455 - (non-HDL-C) and apolipoprotein B. Despite the widespread
060456 - belief that LDL-C is standardized and reproducible,
060457 - available data suggest that results can vary significantly
060458 - as the result of methods from different manufacturers.
060459 - Similar problems with direct HDL-C assays raise concerns
060460 - about the reliability of non-HDL-C measurement.
060462 - ..
060463 - 3. The root cause of method-specific bias relates to the
060464 - ambiguity in the definition of both LDL and HDL, and the
060465 - heterogeneity of LDL and HDL particle size and composition.
060466 -
060467 - [On 111125 2028 CNN television broadcast analysis saying
060468 - measuring LDL cholesterol is not effective for
060469 - evaluating coronary health risks, ref SDS 16 LJ7F,
060470 - recommends measuring small particle LDL cholesterol
060471 - using coronary calcium san techology. ref SDS 16 LW75
060473 - ..
060474 - [On 111128 0202 letter to medical team cites lab today
060475 - reporting LDL 200, ref SDS 17 EA4V, and asks about
060476 - increasing medication to rosuvastatin 20 mg or trying
060477 - some other line of care in order to reduce cholesterol
060478 - LDL < 70, ref SDS 17 EB3U, according to the VA work plan
060479 - on 110817 1030. ref SDS 12 DG36
060481 - ..
060482 - [On 111128 2038 increased medication to rosuvastatin 20 mg,
060483 - shown in case study on patient history on 101010 0744.
060484 - ref SDS 9 NV7I
060486 - ..
060487 - 4. Apolipoprotein B appears to provide a more reliable
060488 - alternative, but assays for it have not been as rigorously
060489 - tested as direct LDL-C and HDL-C assays.
060491 - ..
060492 - 5. Copyright © 2011 National Lipid Association. Published by
060493 - Elsevier Inc. All rights reserved.
060495 - ..
060496 - 6. PMID: 21784371 [PubMed - indexed for MEDLINE]
060497 -
060498 -
060499 -
060501 - ..
060502 - Another article says...
060503 -
060504 - 2. Pubmed.gov
060505 - US National Library of Medicine
060506 - National Institutes of Health
060507 -
060508 - Journal American Medical Association
060510 - ..
060511 - Date.................................... 2011 Aug 24;306(8):831-9
060513 - ..
060514 - Effect of a dietary portfolio of cholesterol-lowering foods
060515 - given at 2 levels of intensity of dietary advice on serum
060516 - lipids in hyperlipidemia: a randomized controlled trial
060517 -
060518 - http://www.ncbi.nlm.nih.gov/pubmed/21862744
060520 - ..
060521 - Authors: Jenkins DJ, Jones PJ, Lamarche B, Kendall CW,
060522 - Faulkner D, Cermakova L, Gigleux I, Ramprasath V, de Souza R,
060523 - Ireland C, Patel D, Srichaikul K, Abdulnour S, Bashyam B,
060524 - Collier C, Hoshizaki S, Josse RG, Leiter LA, Connelly PW,
060525 - Frohlich J.
060527 - ..
060528 - Clinical Nutrition and Risk Factor Modification Center, St
060529 - Michael's Hospital, 61 Queen St E, Toronto, ON M5C 2T2,
060530 - Canada. cyril.kendall@utoronto.ca
060532 - ..
060533 - 1. Abstract
060534 -
060535 - CONTEXT:
060537 - ..
060538 - Combining foods with recognized cholesterol-lowering
060539 - properties (dietary portfolio) has proven highly effective
060540 - in lowering serum cholesterol under metabolically
060541 - controlled conditions.
060543 - ..
060544 - 2. OBJECTIVE:
060545 -
060546 - To assess the effect of a dietary portfolio administered at
060547 - 2 levels of intensity on percentage change in low-density
060548 - lipoprotein cholesterol (LDL-C) among participants
060549 - following self-selected diets.
060551 - ..
060552 - 3. DESIGN, SETTING, AND PARTICIPANTS:
060553 -
060554 - A parallel-design study of 351 participants with
060555 - hyperlipidemia from 4 participating academic centers
060556 - across Canada (Quebec City, Toronto, Winnipeg, and
060557 - Vancouver) randomized between June 25, 2007, and February
060558 - 19, 2009, to 1 of 3 treatments lasting 6 months.
060560 - ..
060561 - 4. INTERVENTION:
060562 -
060563 - Participants received dietary advice for 6 months on either
060564 - a low-saturated fat therapeutic diet (control) or a dietary
060565 - portfolio, for which counseling was delivered at different
060566 - frequencies, that emphasized dietary incorporation of plant
060567 - sterols, soy protein, viscous fibers, and nuts. Routine
060568 - dietary portfolio involved 2 clinic visits over 6 months
060569 - and intensive dietary portfolio involved 7 clinic visits
060570 - over 6 months.
060572 - ..
060573 - 5. MAIN OUTCOME MEASURES:
060574 -
060575 - Percentage change in serum LDL-C.
060577 - ..
060578 - 6. RESULTS:
060579 -
060580 - In the modified intention-to-treat analysis of 345
060581 - participants, the overall attrition rate was not
060582 - significantly different between treatments (18% for
060583 - intensive dietary portfolio, 23% for routine dietary
060584 - portfolio, and 26% for control; Fisher exact test, P =
060585 - .33).
060587 - ..
060588 - 7. The LDL-C reductions from an overall mean of 171 mg/dL (95%
060589 - confidence interval [CI], 168-174 mg/dL) were -13.8% (95%
060590 - CI, -17.2% to -10.3%; P < .001) or -26 mg/dL (95% CI, -31
060591 - to -21 mg/dL; P < .001) for the intensive dietary
060592 - portfolio; -13.1% (95% CI, -16.7% to -9.5%; P < .001) or
060593 - -24 mg/dL (95% CI, -30 to -19 mg/dL; P < .001) for the
060594 - routine dietary portfolio; and -3.0% (95% CI, -6.1% to
060595 - 0.1%; P = .06) or -8 mg/dL (95% CI, -13 to -3 mg/dL; P =
060596 - .002) for the control diet.
060598 - ..
060599 - 8. Percentage LDL-C reductions for each dietary portfolio were
060600 - significantly more than the control diet (P < .001,
060601 - respectively). The 2 dietary portfolio interventions did
060602 - not differ significantly (P = .66). Among participants
060603 - randomized to one of the dietary portfolio interventions,
060604 - percentage reduction in LDL-C on the dietary portfolio was
060605 - associated with dietary adherence (r = -0.34, n = 157, P <
060606 - .001).
060608 - ..
060609 - 9. CONCLUSION:
060610 -
060611 - Use of a dietary portfolio compared with the low-saturated
060612 - fat dietary advice resulted in greater LDL-C lowering
060613 - during 6 months of follow-up.
060614 -
060616 - ..
060617 - 10. TRIAL REGISTRATION:
060618 -
060619 - clinicaltrials.gov Identifier: NCT00438425
060620 -
060622 - ..
060623 - Another article says...
060624 -
060625 - 3. Pubmed.gov
060626 - US National Library of Medicine
060627 - National Institutes of Health
060628 -
060629 - Journal of Pediatrics
060631 - ..
060632 - Date.................................... 1998 Aug;133(2):242-6
060634 - ..
060635 - Month-to-month variability of lipids, lipoproteins, and
060636 - apolipoproteins and the impact of acute infection in
060637 - adolescents.
060638 -
060639 - http://www.ncbi.nlm.nih.gov/pubmed/9709713
060641 - ..
060642 - Authors: Gidding SS, Stone NJ, Bookstein LC, Laskarzewski PM,
060643 - Stein EA.
060645 - ..
060646 - Department of Pediatrics, Northwestern University Medical
060647 - School, Chicago, Illinois, USA.
060648 -
060650 - ..
060651 - 1. Abstract
060652 -
060653 - OBJECTIVE:
060655 - ..
060656 - To assess month-to-month variability of total cholesterol,
060657 - triglycerides, high-density lipoprotein-cholesterol
060658 - (HDL-C), calculated low-density lipoprotein-cholesterol
060659 - (LDL-C), apolipoprotein A1, apolipoprotein B, and
060660 - lipoprotein (a), as well as factors that could influence
060661 - variability, including recent acute infection in an
060662 - adolescent population.
060664 - ..
060665 - 2. METHODS:
060666 -
060667 - Sixty-three high school students had fasting lipids and
060668 - lipoproteins measured at 4 separate times during the school
060669 - year and another venipuncture 3 to 7 days after recovery
060670 - from an acute infection. Erythrocyte sedimentation rate
060671 - was also measured. Coefficients of variation were
060672 - calculated for each study variable. The influence of
060673 - recent infection on variability was assessed.
060675 - ..
060676 - 3. RESULTS:
060677 -
060678 - The 50th and 95th percentiles, respectively, for the
060679 - coefficient of variation for each variable were as follows:
060680 - total cholesterol, 7.3% and 13.6%; triglycerides, 22% and
060681 - 47.3%; HDL-C, 7.9% and 16.8%; LDL-C, 12.1% and 25%;
060682 - apolipoprotein A1, 6.3% and 15.2%; apolipoprotein B, 9.5%
060683 - and 17.2%; and lipoprotein (a), 19.3% and 40%. Recent
060684 - infection significantly lowered HDL-C (4 mg/dL; P < .0001)
060685 - and apolipoprotein A1 (7 mg/dL; P < .005).
060687 - ..
060688 - 4. CONCLUSIONS:
060689 -
060690 - Clinicians evaluating lipids and lipoproteins serially
060691 - should expect significant visit-to-visit variation in
060692 - triglycerides and calculated LDL-C values. Assessment of
060693 - HDL-C and apolipoprotein A1 should not be done within 2
060694 - weeks of an acute infection. Apolipoproteins B and A1 have
060695 - slightly less variability than their respective lipoprotein
060696 - cholesterol values (LDL-C and HDL-C).
060698 - ..
060699 - PMID: 9709713 [PubMed - indexed for MEDLINE]
060700 -
060702 - ..
060703 - Another article says...
060704 -
060705 - 4. Pubmed.gov
060706 - US National Library of Medicine
060707 - National Institutes of Health
060708 -
060709 - Journal of Clinical Lipidology
060711 - ..
060712 - Clin Chem............................... 1988;34(8B):B84-94.
060714 - ..
060715 - Reliability of lipid, lipoprotein, and apolipoprotein
060716 - measurements
060717 -
060718 - http://www.ncbi.nlm.nih.gov/pubmed/3042204
060720 - ..
060721 - Author: Naito, HK
060722 -
060723 - Publications...
060724 -
060725 - http://www.ncbi.nlm.nih.gov/pubmed?term=%22Naito%20HK%22[Author]
060727 - ..
060728 - Department of Biochemistry, Cleveland Clinic Foundation, OH
060729 - 44195.
060731 - ..
060732 - 1. Abstract
060733 -
060734 - The National Heart, Lung, and Blood Institute national
060735 - awareness program on cholesterol and heart disease has
060736 - placed new demands on laboratorians to utilize and perform
060737 - more reliable measurements of lipids, lipoproteins, and
060738 - apolipoproteins.
060740 - ..
060741 - 2. The general public's awareness and the clinicians' concerns
060742 - about the reliability of laboratory testing make it
060743 - paramount that the analytical problems and issues are
060744 - identified and solutions are provided to increase the
060745 - current state of reliability of the measurement of these
060746 - blood constituents. To accomplish this, the initial step
060747 - is to assess the current state of reliability of lipid,
060748 - lipoprotein, and apolipoprotein measurements in the
060749 - clinical laboratories.
060751 - ..
060752 - 3. Accuracy and precision of measurements of total
060753 - cholesterol, triglycerides, high-density lipoprotein
060754 - cholesterol, and apolipoproteins A-I and B are extensively
060755 - discussed, and general as well as some specific
060756 - recommendations are provided for some of the apparent
060757 - problems.
060759 - ..
060760 - PMID: 3042204 [PubMed - indexed for MEDLINE]
060761 -
060762 -
060763 -
060764 -
060765 -
060766 -
0608 -
SUBJECTS
Default Null Subject Account for Blank Record
0703 -
070401 - ..
070402 - Rosuvastatin Side Effects Myopathy Muscle Pain
070403 - Myopathy Muscle Pain Side Effects Rosuvastatin
070404 -
070405 - Follow up ref SDS 14 DO5O. ref SDS 10 JQ5F.
070406 -
070407 - CARDIAC ENZYMES........ 2011 11 17 1427
070408 - PLASMA Results Units Range
070409 - CK 101 IntUnits/L 36 - 340
070410 - TRPONIN ng/ml 0 - 0.07
070411 - CK-MB ng/ml 0.6 - 3.5
070412 - MYOGLOB ng/ml 20 - 82
070413 -
070415 - ..
070416 - CK dropping from 110 for test 4 weeks ago to 111013, ref SDS 14 DO5O,
070417 - down to 101 is not significant.
070419 - ..
070420 - There has been significant improvement in shoulder range of motion
070421 - without pain, reviewed on 111013 1404. ref SDS 12 RG5L This was also
070422 - reported to Doctor Sandhu a few days later on 111018 0800. ref SDS 14
070423 - NP5G
070425 - ..
070426 - Not clear in the record what baseline to use for CK diagnostic, called
070427 - out on 111013 1404. ref SDS 12 RH3K
070428 -
070429 -
070430 -
070431 -
070432 -
070433 -
070434 -
070435 -
070436 -
0705 -